Sarah B. Kavanagh's most recent trade in Bausch + Lomb Corp was a trade of 20,338 Common Shares, No Par Value done . Disclosure was reported to the exchange on May 27, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Bausch Lomb Corp | Sarah B. Kavanagh | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 May 2025 | 20,338 | 53,699 | - | 0 | Common Shares, No Par Value | |
| Bausch Health Companies Inc | Sarah B. Kavanagh | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2025 | 54,347 | 236,359 (0%) | 0% | 0 | Common Shares, No Par Value | |
| Bausch Lomb Corp | Sarah B. Kavanagh | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Aug 2024 | 14,696 | 33,361 | - | 0 | Common Shares, No Par Value | |
| Bausch Health Companies Inc | Sarah B. Kavanagh | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2024 | 35,360 | 182,012 (0%) | 0% | 0 | Common Shares, No Par Value |